Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (21 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15
License and milestone revenue
32
53
71
57
25
20
Collaboration and other revenue
21
18
14
13
17
32
Total revenue
54
72
85
70
42
52
Cost of partnered programs
28
29
24
30
46
44
Research and development for proprietary programs
72
63
57
59
50
54
General and administrative
17
16
15
20
22
31
Total operating expenses
118
109
96
109
118
130
Gain on the Binimetinib and Encorafenib Agreements, net
0
0
0
0
0
80
Gain on sale of CMC, net
0
0
0
0
0
2
Income (loss) from operations
-64
-37
-11
-40
-76
3
Realized gain from marketable securities, net
1
2
0
0
0
16
Loss on prepayment of long-term debt, net
0
-6
-1
-11
0
0
Interest income
1
0
0
0
0
0
Interest expense
-16
-16
-12
-11
-10
-10
Loss before income taxes
-78
0
0
0
0
0
Total other income (expense), net
-14
-20
-13
-22
-10
6
Net Income (Loss)
-78
-56
-24
-62
-85
9
Change in unrealized gains (losses) on marketable securities
2
-6
0
0
0
0
Comprehensive income (loss)
-75
-62
-24
-62
-85
9
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Aug 15, 2014 n/a
calculated values,
restated on Aug 21, 2015 n/a
calculated values,
restated on Aug 21, 2015 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (36 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15
Assets
Cash and cash equivalents
n/a
48
56
61
69
56
Marketable securities
n/a
16
33
48
42
123
Accounts receivable
n/a
0
1
10
5
6
Prepaid expenses and other current assets
n/a
6
3
3
5
6
Total current assets
n/a
71
93
121
122
191
Marketable securities
n/a
1
0
0
1
0
Property and equipment, net
n/a
16
12
10
8
5
Other long-term assets
n/a
2
2
4
6
2
Total long-term assets
n/a
19
15
15
15
7
Total assets
n/a
89
108
136
137
198
Liabilities and owners' equity
Accounts payable
n/a
4 4460000
6 6466000
5 5396000
7 6953000
5 4570000
Accrued outsourcing costs
n/a
5 5248000
5 5394000
6 5576000
10 10040000
17 17402000
Accrued compensation and benefits
n/a
6 6431000
8 7530000
9 9481000
8 8209000
8 7507000
Other accrued expenses
n/a
2 2312000
1 1390000
1 1135000
1 1444000
3 2714000
Co-development liability
n/a
0 0
9 9178000
11 10990000
16 16155000
0 0
Deferred rent
n/a
3 3333000
3 3489000
4 3646000
4 3739000
1 1285000
Deferred revenue
n/a
48 47874000
42 42339000
14 14353000
6 6193000
9 8946000
Current portion of long-term debt
n/a
0 150000
0 150000
0 0
0 0
0 0
Total current liabilities
n/a
70 69808000
76 75936000
51 50577000
53 52733000
42 42424000
Deferred rent
n/a
15 14968000
11 11480000
8 7834000
4 4096000
3 3314000
Deferred revenue
n/a
39 39306000
13 13228000
0 0
3 3353000
2 2040000
Long-term debt, net
n/a
91 91390000
92 92106000
99 99021000
102 101524000
107 107280000
Derivative liabilities
n/a
1 540000
0 0
0 0
0 0
0 0
Other long-term liabilities
n/a
4 4220000
1 1129000
0 465000
1 640000
0 496000
Total long-term liabilities
n/a
150 150424000
118 117943000
107 107320000
110 109613000
113 113130000
Total liabilities
n/a
220 220232000
194 193879000
158 157897000
162 162346000
156 155554000
Commitments and contingencies
n/a
0 0
0 0
0 0
0 0
0 0
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
n/a
0 0
8 8054000
0 0
0 0
0 0
Common stock, $0.001 par value; 220,000,000 shares authorized; 142,107,025 and 131,817,422 shares issued and outstanding as of June 30, 2015 and June 30, 2014, respectively
n/a
0 57000
0 92000
0 117000
0 132000
0 142000
Additional paid-in capital
n/a
347 346853000
437 437401000
571 571270000
653 652696000
751 751073000
Warrants
n/a
39 39385000
39 39385000
39 39385000
39 39385000
0 0
Accumulated other comprehensive income
n/a
0 3000
0 -1000
0 -2000
0 2000
0 5000
Accumulated deficit
n/a
-547 -547156000
-571 -570737000
-633 -632679000
-718 -717936000
-709 -708567000
Total stockholders' equity (deficit)
n/a
-131 -130858000
-86 -85806000
-22 -21909000
-26 -25721000
43 42653000
Total liabilities and stockholders' equity (deficit)
n/a
89 89374000
108 108073000
136 135988000
137 136625000
198 198207000
Remarks restated on n/a restated on Nov 30, -1 n/a restated on Aug 12, 2013 n/a restated on Nov 30, -1 n/a restated on Aug 21, 2015 n/a restated on May 4, 2016 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (36 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15
Net Income (Loss)
-78
-56
-24
-62
-85
9
Depreciation and amortization expense
6
8
5
4
5
4
Non-cash interest expense
7
6
5
4
5
6
Share-based compensation expense
5
3
2
3
4
8
Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net, Available-for-sale Securities
0
0
0
0
0
0
Extinguishment of co-development liability, net
0
0
0
0
0
-22
Realized gain from marketable securities, net
-1
-2
0
0
0
-16
Gain on sale of CMC, net
0
0
0
0
0
-2
Loss on prepayment of long-term debt
0
6
1
11
0
0
Payment of employee bonus with stock
2
4
2
3
0
0
Non-cash license revenue
0
0
0
0
-5
0
Accounts receivable
0
0
1
-9
4
-8
Prepaid expenses and other assets
-1
-1
1
-1
-2
-1
Accounts payable and other accrued expenses
-1
-1
1
-1
2
-1
Accrued outsourcing costs
0
0
0
0
4
7
Accrued compensation and benefits
2
-4
1
2
-1
-1
Co-development liability
0
4
6
2
5
12
Deferred rent
-3
-3
-3
-3
-4
-3
Deferred revenue
78
-30
-32
-41
-5
2
Other long-term liabilities
0
0
0
0
0
0
Net cash used in operating activities
18
-66
-34
-87
-72
-6
Purchases of property and equipment
-1
-2
-1
-2
-3
-3
Proceeds from sale of CMC
0
0
0
0
0
4
Purchases of marketable securities
-79
-53
-51
-111
-96
-203
Proceeds from sales and maturities of marketable securities
11
129
34
97
101
144
Net cash provided by (used) in investing activities
-69
74
-19
-16
2
-58
Proceeds from the issuance of convertible senior notes
40
0
0
132
0
0
Payments of long-term debt principal
0
0
-4
-93
0
0
Proceeds from the issuance of common stock
12
6
67
76
75
48
Proceeds from employee stock purchases and options exercised
1
1
1
2
4
4
Payment of debt issuance costs
-1
0
0
-4
0
0
Payment of stock offering costs
-1
0
-4
-5
-2
-1
Net cash provided by financing activities
51
7
60
108
77
51
Net cash provided by (used in) continuing operations
0
0
0
0
0
0
Net increase (decrease) in cash and cash equivalents
0
15
8
5
8
-13
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Aug 15, 2014 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Sumo